tv.qiagenbioinformatics.com marketingbiox@qiagen.com https://tv.qiagenbioinformatics.com Webinar series focusing on data-driven drug discovery in various therapeutic areas. en-us Visualplatform http://blogs.law.harvard.edu/tech/rss tv.qiagenbioinformatics.com CLC bio TV Watch tutorials, interviews and much more on our web based TV channel! clc bio tv, bioinformatics, genomics, research episodic no https://tv.qiagenbioinformatics.com/files/rv0.0/sitelogo.gif https://tv.qiagenbioinformatics.com http://tv.qiagenbioinformatics.com/photo/126600257/immunology-guide-the-immunology <p><p>The autoimmune drug market is dominated by blockbuster biologics, including Janssen’s Stelara® (ustekinumab), a dual IL-23 and IL-12 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. These biologics generate billions in annual revenue, but when exclusivity ends, competition from biosimilars quickly becomes a concern.</p><p>Using the real-world example of Stelara, which faced multiple new biosimilars within a year of its patent expiry, we explore how to sustain value with smarter lifecycle strategy. We’ll combine data curation, large-scale ‘omics evidence and pathway analytics with QIAGEN Discovery Platform to uncover new opportunities for Stelara.</p><p>In this session, you’ll learn how to:</p><ul><li><p>Support discovery decisions in immunology research</p></li><li><p>Contextualize targets with curated biological knowledge and pathway analytics</p></li><li><p>Identify opportunities for indication expansion and combination strategies</p></li><li><p>Generate AI-ready insights from integrated multimodal data and knowledge graphs</p></li></ul><p>Speakers:</p><p><strong>Tim Hou, PhD</strong></p><p>Senior Field Application Scientist, QIAGEN Digital Insights</p><p>Tim Hou, PhD, is a Senior Field Application Scientist at QIAGEN Digital Insights, where he leverages extensive expertise in molecular biology, genomics and bioinformatics to support researchers with biological data analysis and interpretation platforms from QIAGEN.</p><p><strong>Ethan Strattan, PhD</strong></p><p>Immunology Consulting Scientist, QIAGEN Digital Insights</p><p>Ethan Strattan, PhD, helps clients understand the biological underpinnings of ‘omics-level findings. He works as an immunology and oncology subject matter expert in the QDI Services team, bridging the gap between data scientists and bench researchers. He works with diverse datasets to generate use cases and proof-of-concepts for findings generated from cutting-edge informatics and AI pipelines.&nbsp;</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/126600257/immunology-guide-the-immunology"><img src="http://tv.qiagenbioinformatics.com/64968578/126600257/5226b3cc3b5cf67d8062c3208b78da12/standard/download-14-thumbnail.jpg" width="600" height="338"/></a></p> http://tv.qiagenbioinformatics.com/photo/126600257 Tue, 05 May 2026 17:32:26 GMT Immunology: Guide the immunology drug discovery lifecycle with ‘omics... The autoimmune drug market is dominated by blockbuster biologics, including Janssen’s Stelara® (ustekinumab), a dual IL-23 and IL-12 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. These biologics generate billions in annual revenue, but when exclusivity ends, competition from biosimilars quickly becomes a concern.Using the real-world example of Stelara, which faced multiple new biosimilars within a year of its patent expiry, we explore how to sustain value with smarter lifecycle strategy. We’ll combine data curation, large-scale ‘omics evidence and pathway analytics with QIAGEN Discovery Platform to uncover new opportunities for Stelara.In this session, you’ll learn how to:Support discovery decisions in immunology researchContextualize targets with curated biological knowledge and pathway analyticsIdentify opportunities for indication expansion and combination strategiesGenerate AI-ready insights from integrated multimodal data and knowledge graphsSpeakers:Tim Hou, PhDSenior Field Application Scientist, QIAGEN Digital InsightsTim Hou, PhD, is a Senior Field Application Scientist at QIAGEN Digital Insights, where he leverages extensive expertise in molecular biology, genomics and bioinformatics to support researchers with biological data analysis and interpretation platforms from QIAGEN.Ethan Strattan, PhDImmunology Consulting Scientist, QIAGEN Digital InsightsEthan Strattan, PhD, helps clients understand the biological underpinnings of ‘omics-level findings. He works as an immunology and oncology subject matter expert in the QDI Services team, bridging the gap between data scientists and bench researchers. He works with diverse datasets to generate use cases and proof-of-concepts for findings generated from cutting-edge informatics and AI pipelines. The autoimmune drug market is dominated by blockbuster biologics, including Janssen’s Stelara® (ustekinumab), a dual IL-23 and IL-12 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. These... tv.qiagenbioinformatics.com 57:15 <p><p>The autoimmune drug market is dominated by blockbuster biologics, including Janssen’s Stelara® (ustekinumab), a dual IL-23 and IL-12 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. These biologics generate billions in annual revenue, but when exclusivity ends, competition from biosimilars quickly becomes a concern.</p><p>Using the real-world example of Stelara, which faced multiple new biosimilars within a year of its patent expiry, we explore how to sustain value with smarter lifecycle strategy. We’ll combine data curation, large-scale ‘omics evidence and pathway analytics with QIAGEN Discovery Platform to uncover new opportunities for Stelara.</p><p>In this session, you’ll learn how to:</p><ul><li><p>Support discovery decisions in immunology research</p></li><li><p>Contextualize targets with curated biological knowledge and pathway analytics</p></li><li><p>Identify opportunities for indication expansion and combination strategies</p></li><li><p>Generate AI-ready insights from integrated multimodal data and knowledge graphs</p></li></ul><p>Speakers:</p><p><strong>Tim Hou, PhD</strong></p><p>Senior Field Application Scientist, QIAGEN Digital Insights</p><p>Tim Hou, PhD, is a Senior Field Application Scientist at QIAGEN Digital Insights, where he leverages extensive expertise in molecular biology, genomics and bioinformatics to support researchers with biological data analysis and interpretation platforms from QIAGEN.</p><p><strong>Ethan Strattan, PhD</strong></p><p>Immunology Consulting Scientist, QIAGEN Digital Insights</p><p>Ethan Strattan, PhD, helps clients understand the biological underpinnings of ‘omics-level findings. He works as an immunology and oncology subject matter expert in the QDI Services team, bridging the gap between data scientists and bench researchers. He works with diverse datasets to generate use cases and proof-of-concepts for findings generated from cutting-edge informatics and AI pipelines.&nbsp;</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/126600257/immunology-guide-the-immunology"><img src="http://tv.qiagenbioinformatics.com/64968578/126600257/5226b3cc3b5cf67d8062c3208b78da12/standard/download-14-thumbnail.jpg" width="600" height="338"/></a></p> drug discovery http://tv.qiagenbioinformatics.com/photo/126774951/oncology-de-risking-target <p><p>The early stages of drug development are inherently high-risk; molecule screening, target evaluation and lead refinement can take years and cost millions of dollars – often have little to show for the effort. Indication expansion and drug repurposing can open new avenues of possibility, after careful evaluation of the relationships between the drug, its targets and the new disease context. These connections can be uncovered by mining curated, causal knowledge graphs, which inform smarter target identification.</p><p>Learn how to evaluate targets and drugs in this oncology-focused webinar, which examines BRAF as a target in multiple myeloma. Also, we’ll evaluate different drugs in clinical trials with an analysis that covers the GOT-IT assessment blocks for drug evaluation. These blocks, developed by the GOT-IT (Guidelines On Target Assessment for Innovative Therapeutics) working group, are part of a target assessment framework that supports robust, reproducible data.</p><p><strong>We’ll cover how to:</strong></p><ul><li><p>Apply the GOT-IT framework to target evaluation and indication expansion</p></li><li><p>Uncover causal relationships between existing drugs and new diseases with our curated knowledge graphs</p></li><li><p>Make informed decisions based on concrete data, including toxicity, adverse events and competing drugs in clinical trials</p></li></ul><p>Speakers:</p><p><strong>Sathiya Manivannan, PhD</strong></p><p>Scientific Consulting Expert (Multiomics), QIAGEN Digital Insights</p><p>Sathiya Manivannan, PhD,&nbsp;delivers tailored solutions for pharmaceutical and biotech companies. His work includes large-scale single-cell and spatial transcriptomics analyses, multi-omics database generation, and the development of graph knowledge bases and AI/ML-driven solutions that accelerate therapeutic target discovery and optimize drug development.</p><p><strong>Ruth Stoney, PhD</strong></p><p>Senior Field Application Scientist, QIAGEN Digital Insights</p><p>Ruth Stoney, PhD, designs data science projects for customers using ‘omics datasets and insights mined from the QDI knowledge graph. She collaborates with academics and biopharma data scientists on biological discovery, AI usage and more.</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/126774951/oncology-de-risking-target"><img src="http://tv.qiagenbioinformatics.com/64968567/126774951/9f10fcd6e1dbff137d7380963d499670/standard/download-17-thumbnail.jpg" width="600" height="338"/></a></p> http://tv.qiagenbioinformatics.com/photo/126774951 Tue, 05 May 2026 17:32:22 GMT Oncology: De-risking target evaluation and indication expansion with curated... The early stages of drug development are inherently high-risk; molecule screening, target evaluation and lead refinement can take years and cost millions of dollars – often have little to show for the effort. Indication expansion and drug repurposing can open new avenues of possibility, after careful evaluation of the relationships between the drug, its targets and the new disease context. These connections can be uncovered by mining curated, causal knowledge graphs, which inform smarter target identification.Learn how to evaluate targets and drugs in this oncology-focused webinar, which examines BRAF as a target in multiple myeloma. Also, we’ll evaluate different drugs in clinical trials with an analysis that covers the GOT-IT assessment blocks for drug evaluation. These blocks, developed by the GOT-IT (Guidelines On Target Assessment for Innovative Therapeutics) working group, are part of a target assessment framework that supports robust, reproducible data.We’ll cover how to:Apply the GOT-IT framework to target evaluation and indication expansionUncover causal relationships between existing drugs and new diseases with our curated knowledge graphsMake informed decisions based on concrete data, including toxicity, adverse events and competing drugs in clinical trialsSpeakers:Sathiya Manivannan, PhDScientific Consulting Expert (Multiomics), QIAGEN Digital InsightsSathiya Manivannan, PhD,delivers tailored solutions for pharmaceutical and biotech companies. His work includes large-scale single-cell and spatial transcriptomics analyses, multi-omics database generation, and the development of graph knowledge bases and AI/ML-driven solutions that accelerate therapeutic target discovery and optimize drug development.Ruth Stoney, PhDSenior Field Application Scientist, QIAGEN Digital InsightsRuth Stoney, PhD, designs data science projects for customers using ‘omics datasets and insights mined from the QDI knowledge graph. She collaborates with academics and biopharma data scientists on biological discovery, AI usage and more. The early stages of drug development are inherently high-risk; molecule screening, target evaluation and lead refinement can take years and cost millions of dollars – often have little to show for the effort. Indication expansion and drug... tv.qiagenbioinformatics.com 58:10 <p><p>The early stages of drug development are inherently high-risk; molecule screening, target evaluation and lead refinement can take years and cost millions of dollars – often have little to show for the effort. Indication expansion and drug repurposing can open new avenues of possibility, after careful evaluation of the relationships between the drug, its targets and the new disease context. These connections can be uncovered by mining curated, causal knowledge graphs, which inform smarter target identification.</p><p>Learn how to evaluate targets and drugs in this oncology-focused webinar, which examines BRAF as a target in multiple myeloma. Also, we’ll evaluate different drugs in clinical trials with an analysis that covers the GOT-IT assessment blocks for drug evaluation. These blocks, developed by the GOT-IT (Guidelines On Target Assessment for Innovative Therapeutics) working group, are part of a target assessment framework that supports robust, reproducible data.</p><p><strong>We’ll cover how to:</strong></p><ul><li><p>Apply the GOT-IT framework to target evaluation and indication expansion</p></li><li><p>Uncover causal relationships between existing drugs and new diseases with our curated knowledge graphs</p></li><li><p>Make informed decisions based on concrete data, including toxicity, adverse events and competing drugs in clinical trials</p></li></ul><p>Speakers:</p><p><strong>Sathiya Manivannan, PhD</strong></p><p>Scientific Consulting Expert (Multiomics), QIAGEN Digital Insights</p><p>Sathiya Manivannan, PhD,&nbsp;delivers tailored solutions for pharmaceutical and biotech companies. His work includes large-scale single-cell and spatial transcriptomics analyses, multi-omics database generation, and the development of graph knowledge bases and AI/ML-driven solutions that accelerate therapeutic target discovery and optimize drug development.</p><p><strong>Ruth Stoney, PhD</strong></p><p>Senior Field Application Scientist, QIAGEN Digital Insights</p><p>Ruth Stoney, PhD, designs data science projects for customers using ‘omics datasets and insights mined from the QDI knowledge graph. She collaborates with academics and biopharma data scientists on biological discovery, AI usage and more.</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/126774951/oncology-de-risking-target"><img src="http://tv.qiagenbioinformatics.com/64968567/126774951/9f10fcd6e1dbff137d7380963d499670/standard/download-17-thumbnail.jpg" width="600" height="338"/></a></p> drug discovery